NeuBase to Participate at Chardan’s 6th Annual Genetic Medicines Conference
Get Alerts NBSE Hot Sheet
Join SI Premium – FREE
PITTSBURGH and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced that company management will participate in-person for a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference being held in New York City on October 3-4, 2022.
| Details of the presentation are as follows: | ||
| Date: | Monday, October 3rd | |
| Time: | 9:00am – 9:25am ET | |
| Format: | Fireside Chat | |
An audio replay of the webcast will be available following the presentation for 90 days. To access the replay, please click here. Please contact your representative at Chardan to schedule a one-on-one meeting with NeuBase management during the conference. About NeuBase TherapeuticsNeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines that Drug the Genome™. The Company’s therapies are built on a proprietary platform called PATrOL™ that encompasses a novel peptide-nucleic acid antisense oligonucleobase technology combined with a novel delivery shuttle that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions, who currently have limited to no treatment options. To learn more, visit www.neubasetherapeutics.com.
NeuBase Investor Contact: Daniel FerryManaging Director LifeSci Advisors, LLC [email protected] OP: (617) 430-7576
NeuBase Media Contact:Jessica Yingling, Ph.D.PresidentLittle Dog Communications Inc.[email protected]OP: (858) 344-8091
Source: NeuBase Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Comstock Receives $20 Million and Closes Sale of Legacy Mining Assets to Mackay Precious Metals Inc.
- Mesta Launches their White-Labeled Customer Portal as Infrastructure Emerges as the Next Frontier in Global Payments
- Lookthrough and BuildingMinds Join Forces to Build the Leading AI Platform for Real Estate Decision Intelligence
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Chardan Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share